P8A:SGX
Cordlife Group Ltd
0,12 SGD
0,00%
(0,00) 1 T
12. Okt., 09:49:20 GMT+8 · SGD
search
Alle Symbole
| Symbol | Kurs | Änderung | Änderung in % |
|---|
insights_autoWichtige Einblicke für P8A werden generiert…
Börsenwert
32,37 Mio.
Durchschn. HVol.
1320,00
Handelsvolumen
0,00
52-Wochen-Hoch
0,26 SGD
52-Wochen-Tief
0,10 SGD
EPS
-0,04 SGD
Aktien im Umlauf
267,53 Mio.
Anzahl der Mitarbeiter
111
Börsenwert
32,37 Mio.
Durchschn. HVol.
1320,00
Handelsvolumen
0,00
52-Wochen-Hoch
0,26 SGD
52-Wochen-Tief
0,10 SGD
EPS
-0,04 SGD
Aktien im Umlauf
267,53 Mio.
Anzahl der Mitarbeiter
111
Nachrichtenmeldungen
Aus Webquellen und von Nachrichtenpartnern
Wallstreet Online
·
vor 4 Stunden
Aktien mit extremer Performance im US 500 am 15.10.2026
Investing.com Deutsch
·
vor 3 Stunden
ROUNDUP/Aktien New York Schluss: Techwerte erholen sich - Dow steigt deutlich Von dpa-AFX
Finanzen.net
·
vor 3 Stunden
Freundlicher Handel: S&P 500 beendet den Donnerstagshandel im Plus
TradingView
·
vor 4 Stunden
MÄRKTE-US-Index Dow Jones schließt 1,1 Prozent höher bei 52.177,69 Punkten
Profil
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn.
In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
Über Cordlife Group Ltd